Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com
HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Fiber Intake Associated With Lower Mortality in Patients with Colorectal Cancer
November 3rd 2017

Fiber Intake Associated With Lower Mortality in Patients with Colorectal Cancer

Jaime Rosenberg
Increased fiber, especially from cereal, intake after the diagnosis of non-metastatic colorectal cancer (CRC) is associated with lower CRC-specific and overall mortality.
FDA Approves New Treatment for Adults With Mantle Cell Lymphoma
November 1st 2017

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

Jaime Rosenberg
Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.
FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer
November 1st 2017

FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer

Alison Rodriguez
The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.
Evidence-Based OncologyTM Highlights Role of Pharmacist in Cancer Care
November 1st 2017

Evidence-Based OncologyTM Highlights Role of Pharmacist in Cancer Care

As cancer care becomes more expensive and complex, the role of the pharmacist is expanding, from managing the shift to greater use of oral therapies to navigating the revenue cycle, as explored in the new issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care.®
Educating Patients About Risk of Febrile Neutropenia Associated With Strong Chemotherapy
October 31st 2017

Educating Patients About Risk of Febrile Neutropenia Associated With Strong Chemotherapy

AJMC Staff
Strong chemotherapy may be part of the treatment plan for patients diagnosed with cancer, but it also comes with risks. A new campaign will empower patients with cancer to better understand and navigate risks such as febrile neutropenia that are associated with strong chemotherapy.
70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer
October 31st 2017

70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer

Jaime Rosenberg
Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.
Site Logo
October 30th 2017

Data Challenges Under the Oncology Care Model

Darcie Hurteau
An overview of factors that make the Oncology Care Model performance period data challenging to navigate and use.
Global Cancer Burden in Young Adults Differs From That in Other Age Groups
October 30th 2017

Global Cancer Burden in Young Adults Differs From That in Other Age Groups

Jaime Rosenberg
A new study found that the global cancer burden in young adults differs from that in younger and older age groups and was more common in women.
ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen
October 29th 2017

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

Alison Rodriguez
Results of the Phase 3 ARROW trial revealed that patiehts with refractory multiple myeloma can live up to 3.6 months longer, without their disease worsening, when Kyprolis (carfilzomib) is administered once-weekly at the 70 mg/m2 dose with dexamethasone rather than Kyprolis administered twice-weekly at the 27 mg/m2 dose with dexamethasone, according to Amgen.
Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities
October 28th 2017

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

Alison Rodriguez
Study Finds Need for Standardization of Immune Checkpoint Inhibitor Assays in NSCLC
October 28th 2017

Study Finds Need for Standardization of Immune Checkpoint Inhibitor Assays in NSCLC

Alison Rodriguez
Site Logo
October 27th 2017

Expanding Options for Individualized Treatment of Advanced NSCLC

Christina Mattina
James R. Jett, MD, gave an overview of the advances in diagnosis and treatment of non–small cell lung cancer (NSCLC) during a session at the National Association of Managed Care Physicians Fall Managed Care Forum 2017.
Childhood Cancer Survivors Face Job Lock to Keep Insurance Coverage
October 27th 2017

Childhood Cancer Survivors Face Job Lock to Keep Insurance Coverage

Alison Rodriguez
Many of survivors of childhood cancer who are now within the prime age for labor force participation are reluctant to make changes in their employment because of access to health insurance, and therefore, job lock is common among this population.
Site Logo
October 26th 2017

Survey: Americans Have High Concerns About Cancer, Low Awareness of Risk Factors

Kelly Davio
Results of the first annual National Cancer Opinion Survey, established by the American Society of Clinical Oncology (ASCO), show that the majority of Americans are unaware of several key risk factors for cancer, and that a minority are taking active steps to reduce their personal risk.
Site Logo
October 25th 2017

Stakeholders Weigh-in on Payment Reform in Cancer Care

Surabhi Dangi-Garimella, PhD
Tuple Health, a healthcare technology startup, interviewed some of the stakeholders participating in value-based care delivery and OCM, to gain their perspective of the state of cancer care and healthcare reform. The results were presented at the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform.
Site Logo
October 25th 2017

The Commercial Payer OCM Experience: Year 1

Surabhi Dangi-Garimella, PhD
Representatives from 3 payers who partnered with providers on the Oncology Care Model (OCM) took the stage at Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform to outline their experience with OCM and how it has differed from other care models.
Terrill Jordan: Education and Data Are Key for OCM Success
October 25th 2017

Terrill Jordan: Education and Data Are Key for OCM Success

Education is key to succeed in the Oncology Care Model, but presenting data in a simple format for clinicians to use is also critical, said Terrill Jordan, CEO, of Regional Cancer Care Associates.
Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia
October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez
Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
October 25th 2017

Physicians Need Clearer Metrics Before Taking on 2-Sided Risk

Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.
Site Logo
October 25th 2017

The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma

Julia Thornton Snider, PhD Katharine Batt, MD, MSc Yanyu Wu, PhD Mahlet Gizaw Tebeka, MS Seth Seabury, PhD
Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.
Site Logo
October 24th 2017

Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM

The implementation of the Oncology Care Model has brought profound culture changes to how oncologists take care of patients and how they operate practices, explained Lucio Gordan, MD, of Florida Cancer Specialists.
Site Logo
October 24th 2017

Will 2-Sided Risk Be a Reality in OCM?

Kelly Davio
With the Oncology Care Model now in its second year, 3 representatives discussed learnings and how the program can change, as well as incentivizing physicians to accept 2-sided risk, the ability to engage additional payers, and the future of oncology bundle payments.
Site Logo
October 24th 2017

How Has the OCM Evolved? Year 1 Provider Updates

Surabhi Dangi-Garimella, PhD
Participants from 2 oncology community practices—an oncologist–administrator combination—shared their experience with implementing the Oncology Care Model (OCM) with attendees at the Community Oncology Alliance’s Payer Exchange Summit on Oncology Payment Reform, held October 23-24, in Tysons Corner, Virginia.
Site Logo
October 24th 2017

Study: Prophylactic Up-Front Locoregional Surgery Has No Survival Advantage

Jaime Rosenberg
The study found that prophylactic locoregional surgery (LRS) for asymptomatic patients with small intestinal neuroendocrine tumors (SI-NETs) provided no survival advantage compared with delayed LRS.
Site Logo
October 23rd 2017

Increased Insurance Coverage Seen Under the ACA for Patients With Cancer

Jaime Rosenberg
A new study has found that uninsurance rates declined the most in patients with distant disease and with lung and bronchial cancer. Hispanic patients also saw a large decrease in uninsurance rates.
Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News
October 21st 2017

Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: October 20, 2017
October 20th 2017

This Week in Managed Care: October 20, 2017

This week, the top managed care news included the bipartisan deal to stabilize the Affordable Care Act's insurance markets; coverage from the Academy of Managed Care Pharmacy 2017 Nexus; and a plan to reduce clinician burnout at the computer.
Site Logo
October 19th 2017

Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel

Surabhi Dangi-Garimella, PhD
Axicabtagene ciloleucel (Yescarta) has been approved to treat adult patients with diffuse large B-cell lymphoma who have not responded to or who have relapsed after at least 2 other kinds of treatment.
Site Logo
October 18th 2017

PD-1 Inhibitor Doubled Survival in Treatment-Naive Patients With mNSCLC

Surabhi Dangi-Garimella, PhD
The 2-year follow up results from the Keynote-024 trial were presented at the 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan.
Site Logo
October 18th 2017

Increasing Levels of CD8+ TILs Prolong Survival in High-Grade Serous Ovarian Cancer

Jaime Rosenberg
There is a relationship between CD8+ tumor infiltrating lymphocytes (TILs) and high-grade serous ovarian carcinoma (HGSOC) survival, according to a new study published in JAMA Oncology.
<1
...
626364656667686970
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo